Investigating the mechanisms of drug sensitivity and resistance to targeted therapies for lung cancer.

Main Header
Go to Research

Featured Publication

Therapy-induced APOBEC3A drives evolution of persistent cancer cells.

Published July 5, 2023
See all Publications

Aaron Hata, MD PhD, Principal Investigator


Our mission is to advance the development of new therapies for patients with lung cancer through scientific discovery of the molecular mechanisms of drug sensitivity and resistance, understanding tumor evolution during treatment, and identification of targetable vulnerabilities to guide investigation of novel therapeutic strategies.

We are a diverse group of physicians & scientists with expertise in cell biology, pharmacology, genetics, immunology and computational biology. We are currently recruiting at all levels - if you would like to join our team, please contact us.

Meet the Team

News — August 4, 2023


We say farewell to Luke who will be attending the University of Utah in the Molecular Biology PhD program. Best wishes to you in your future endeavors – we will…

Go to News

News — August 4, 2023


We say farewell to Sarah who will be starting as a research technician for lymphoma research in the Roth Lab at Weill Cornell Medicine. Best wishes to you in your…

Go to News

We are looking for people to partner with us in our mission to improve treatments for patients with lung cancer.

Join Us Support Us